Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2025/2026 influenza season

as of September 18, 2026; November 9, 2026 updated

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	0	1 (0.6%)	1 (0.6%)	0	0	104 (100%)	12 (1.0%)	0	0	0	0	339 (100%)	0	0	0	0	0
Number of viruses tested	139	170	170	88	88	104	1,177	336	336	336	336	339	492	231	231	231	231
Number of viruses reported	324						5,638						3,962				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.